Kodiak Sciences Inc.
KOD
Kedudukan dalam Saham
#3149
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical... Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
Harga Saham
$90.83
Disegerakkan terakhir: 2026-10-19
Modal Pasaran
$5.71B
Perubahan (1 hari)
5.92%
Perubahan (1 tahun)
413.16%
Negara
US
Perdagangan Kodiak Sciences Inc. (KOD)
Kategori
Healthcare
Pendapatan untuk Kodiak Sciences Inc. (KOD)
Pendapatan pada Jun 2026 TTM: $-241.99M
Menurut laporan kewangan terkini Kodiak Sciences Inc., pendapatan semasa syarikat ialah $-241.99M. Pada tahun 2023, syarikat memperoleh pendapatan sebanyak $-260.49M, peningkatan berbanding pendapatan pada tahun 2022 yang berjumlah $-333.82M. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Kodiak Sciences Inc. dari 2016 hingga 2026
Pendapatan pada akhir setiap tahun
| Tahun | Pendapatan | Ubah |
|---|---|---|
| 2026 (TTM) | $-241.99M | 37.34% |
| 2024 | $-176.21M | -32.36% |
| 2023 | $-260.49M | -21.97% |
| 2022 | $-333.82M | 25.03% |
| 2021 | $-266.99M | 100.60% |
| 2020 | $-133.10M | 181.00% |
| 2019 | $-47.37M | 14.29% |
| 2018 | $-41.44M | 48.35% |
| 2017 | $-27.94M | 63.06% |
| 2016 | $-17.13M | 0.00% |
Pendapatan untuk syarikat atau pesaing serupa
| Syarikat | Pendapatan | Perbezaan Pendapatan | Negara |
|---|---|---|---|
| $5.27B | -2,279.76% |
US
|
|
| $-3.09B | 1,175.65% |
US
|
|
| $-4.02B | 1,559.63% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -906.07% |
NL
|
